Prognostic Factors in Elderly Patients with Diffuse Large B-Cell Lymphoma and Their Treatment Results

摘要

Objective: Diffuse large B-cell lymphoma (DLBCL) is the mostcommon type of non-Hodgkin lymphoma (NHL). The treatment ofolder NHL patients has always been a struggle; however, treatmentstatistics have begun showing favorable results similar to those ofyounger DLBCL patients thanks to newer treatment protocols. Here,we analyze the progress of our own elderly DLBCL patients who werefollowed between 2000 and 2016 in our center.Materials and Methods: Eighty-seven DLBCL patients, who werediagnosed and treated in the Dokuz Eylül University Department ofHematology between 2000 and 2016, were included in this study.Median age was 72 (65-89) years and 13 (14.9%) patients were olderthan 80 years.Results: Median follow-up time was 19 months and 45 patients(51.7%) died during the follow-up period. Median overall survival (OS)was 55 months and median progression-free survival was calculatedas 27 months. Sixty-three patients (72.4%) received standard R-CHOPtherapy. Complete response was seen in 46 (52.9%) patients. Themedian survival time for patients who had complete response was 136months (p80 years) and younger patients (p=0.236).Conclusion: According to our findings, we think that being able tocomplete standard R-CHOP therapy is vital for the survival rate ofelderly DLBCL patients.